Is there still a need for specific central nervous system directed prophylaxis for diffuse large B-cell lymphoma in the rituximab era?

Leuk Lymphoma. 2014 Mar;55(3):471-3. doi: 10.3109/10428194.2013.830306. Epub 2013 Nov 14.

Authors

Chan Y Cheah¹, John F Seymour

Affiliation

¹ Department of Haematology, Peter MacCallum Cancer Centre , East Melbourne, Victoria , Australia and University of Melbourne , Parkville, Victoria , Australia.

PMID: 23906017
DOI: 10.3109/10428194.2013.830306

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal, Murine-Derived / therapeutic use*
Antineoplastic Agents / therapeutic use*
Central Nervous System Neoplasms / drug therapy*
Central Nervous System Neoplasms / pathology*
Humans
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Lymphoma, Large B-Cell, Diffuse / pathology*
Rituximab

Substances

Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents
Rituximab